December 26, 2018
RaQualia Pharma said on December 21 that South Korea’s CJ HealthCare, a licensee of its investigational potassium-competitive acid blocker (P-CAB) tegoprazan, entered into a sublicense agreement for the compound with Vimedimex Medi-Pharma of Vietnam. The deal will trigger an upfront...read more